At 0 2 0 2 O
randomization 3 16 3 16 O
, 16 17 16 17 O
their 18 23 18 23 O
planned 24 31 24 31 O
course 32 38 32 38 O
of 39 41 39 41 O
antibacterial 42 55 42 55 B-treatment
drug 56 60 56 60 I-treatment
treatment 61 70 61 70 I-treatment
for 71 74 71 74 O
CDI 75 78 75 78 B-chronic_disease
is 79 81 79 81 O
longer 82 88 82 88 O
than 89 93 89 93 O
21 94 96 94 96 B-lower_bound
days 97 101 97 101 I-lower_bound

At 0 2 102 104 O
screening 3 12 105 114 O
has 13 16 115 118 O
received 17 25 119 127 O
any 26 29 128 131 O
listed 30 36 132 138 O
prohibited 37 47 139 149 O
prior 48 53 150 155 O
and 54 57 156 159 O
concomitant 58 69 160 171 B-treatment
treatments 70 80 172 182 I-treatment
and 81 84 183 186 O
procedures 85 95 187 197 O

At 0 2 198 200 O
screening 3 12 201 210 O
has 13 16 211 214 O
suspected 17 26 215 224 O
or 27 29 225 227 O
confirmed 30 39 228 237 O
CDI 40 43 238 241 B-chronic_disease

Has 0 3 242 245 O
a 4 5 246 247 O
known 6 11 248 253 O
hypersensitivity 12 28 254 270 O
to 29 31 271 273 O
bezlotoxumab 32 44 274 286 B-allergy_name

Has 0 3 287 290 O
an 4 6 291 293 O
uncontrolled 7 19 294 306 O
chronic 20 27 307 314 B-chronic_disease
diarrheal 28 37 315 324 I-chronic_disease
illness 38 45 325 332 I-chronic_disease

Has 0 3 333 336 O
received 4 12 337 345 O
an 13 15 346 348 O
investigational 16 31 349 364 B-treatment
study 32 37 365 370 I-treatment
agent 38 43 371 376 I-treatment
within 44 50 377 383 O
the 51 54 384 387 O
previous 55 63 388 396 B-upper_bound
30 64 66 397 399 I-upper_bound
days 67 71 400 404 I-upper_bound

for 0 3 405 408 O
at 4 6 409 411 O
least 7 12 412 417 O
12 13 15 418 420 B-lower_bound
weeks 16 21 421 426 I-lower_bound
after 22 27 427 432 O
the 28 31 433 436 O
last 32 36 437 441 O
dose 37 41 442 446 O
of 42 44 447 449 O
study 45 50 450 455 O
treatment 51 60 456 465 O

has 0 3 466 469 O
received 4 12 470 478 O
a 13 14 479 480 O
vaccine 15 22 481 488 B-treatment
directed 23 31 489 497 O
against 32 39 498 505 O
C 40 41 506 507 O

is 0 2 508 510 O
currently 3 12 511 520 O
participating 13 26 521 534 O
in 27 29 535 537 O
or 30 32 538 540 O
scheduled 33 42 541 550 O
to 43 45 551 553 O
participate 46 57 554 565 O
in 58 60 566 568 O
any 61 64 569 572 O
other 65 70 573 578 B-treatment
clinical 71 79 579 587 I-treatment
study 80 85 588 593 I-treatment
with 86 90 594 598 O
an 91 93 599 601 O
investigational 94 109 602 617 O
agent 110 115 618 623 O
during 116 122 624 630 O
the 123 126 631 634 O
12 127 129 635 637 O
- 129 130 637 638 O
week 130 134 638 642 O
study 135 140 643 648 O
period 141 147 649 655 O

receiving 0 9 656 665 O
or 10 12 666 668 O
is 13 15 669 671 O
planning 16 24 672 680 O
to 25 27 681 683 O
receive 28 35 684 691 O
a 36 37 692 693 O
10- 38 41 694 697 B-lower_bound
to 42 44 698 700 O
21 45 47 701 703 B-upper_bound
- 47 48 703 704 I-upper_bound
day 48 51 704 707 I-upper_bound
course 52 58 708 714 O
of 59 61 715 717 O
antibacterial 62 75 718 731 B-treatment
drug 76 80 732 736 I-treatment
treatment 81 90 737 746 I-treatment
for 91 94 747 750 O
CDI 95 98 751 754 B-chronic_disease

still 0 5 755 760 O
receiving 6 15 761 770 O
antibacterial 16 29 771 784 B-treatment
drug 30 34 785 789 I-treatment
treatment 35 44 790 799 I-treatment
for 45 48 800 803 O
CDI 49 52 804 807 B-chronic_disease

